布地奈德福莫特罗联合噻托溴铵对AECOPD患者血管内皮功能及肺通气功能的改善作用OA

Objective:To evaluate the therapeutic effectiveness of a combined therapeutic strategy involving budesonide formoterol and tiotropium bromide in patients with acute exacerbation of chronic obstructive pulmonary disease(AECOPD).Method:This prospective randomized controlled research recruited 102 AECOPD patients who received treatment at Pucheng County Hospital between March 2023 and May 2025.All the patients were randomly divided into two groups by using the random number table method.The control group(51 cases)were treated with budesonide formoterol alone,while the research group(51 cases)were given combined therapy with budesonide formoterol plus tiotropium bromide.Clinical therapeutic effects,respiratory function parameters,inflammatory biomarkers,endothelial function,and adverse events were evaluated and compared between the two groups.Result:Compared with the control group,the total effective rate of the research group was remarkably higher.After the treatment was completed,forced expiratory volume in the first second(FEV1),maximal mid-expiratory flow(MMEF),minute maximum ventilation(MVV),and nitric oxide(NO)in the research group were all higher than those in the control group.In addition,the levels of endothelin-1(ET-1),leukotriene B4(LTB4),tumor necrosis factor alpha(TNF-α),and C-reactive protein(CRP)in the research group were lower than those in the control group,and all these indicator differences were all statistically significant(P<0.05).The occurrence of adverse reactions was compared between the two groups,and the difference was not statistically significant(P>0.05).Conclusion:The combination therapy of budesonide,formoterol,and tiotropium bromide provides a distinct therapeutic benefit in the management of AECOPD.It not only enhances pulmonary ventilatory function and inhibits inflammatory reactions but also improves endothelial function,accompanied by a favorable safety profile.